Lumos Pharma Delays Data Readout From Pediatric Growth Hormone Deficiency Trial To 2H Of 2023

Lumos Pharma Inc LUMO expects 6-month primary outcome data from Phase 2 OraGrowtH210 Trial of LUM-201 in the 2H of 2023, citing the pace of site initiation and slower than anticipated enrollment due to COVID-19 restrictions.

  • Earlier, the data read-out for the OraGrowtH210 Trial was expected in mid-2022.
  • The OraGrowtH210 trial of LUM-201 is targeting Pediatric Growth Hormone Deficiency (PGHD).
  • The FDA has also requested an extension of the OraGrowtH210 Trial to 12 months. 
  • The planned protocol extension mirrors the first six months of the OraGrowtH211 long-term extension study. 
  • The agency has placed its planned long-term extension study on partial clinical hold until additional efficacy data from the OraGrowtH210 Trial are available to be reviewed. 
  • Also, the OraGrowtH212 Trial of LUM-201 in PGHD will be extended from six months to twelve months to capture additional PK/PD and height velocity data.
  • The PD pulsatility assessment will continue to be at six months on therapy as planned.
  • The Company will hold a conference call and webcast for today at 8:30 a.m. ET.
  • Price Action: LUMO shares closed at $9.37 on Tuesday.
  • Related content: Benzinga's Full FDA Calendar.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareFDAGeneralBriefsPediatrics
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!